HCAR2 antibody (AA 200-228)

Catalog No. ABIN5536145

This Rabbit Polyclonal antibody specifically detects HCAR2 in WB. It exhibits reactivity toward Human.

Quick Overview for HCAR2 antibody (AA 200-228) (ABIN5536145)

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HCAR2 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-HCAR2 Antibody

Binding Specificity: AA 200-228

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This NIACR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 200-228 amino acids from the Central region of human NIACR1.

Isotype: Ig Fraction

Application Details

Application Notes: For WB starting dilution is: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for HCAR2

Target: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Alternative Name: NIACR1

Background: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Molecular Weight: 42 kDa

Gene ID: 338442

UniProt: Q8TDS4